Cargando…

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6

OBJECTIVE: To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo‐controlled, phase 3 trial in patients with drug‐resistant epilepsy associated with tuberous sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Joyce Y., Cock, Hannah R., Devinsky, Orrin, Joshi, Charuta, Miller, Ian, Roberts, Colin M., Sanchez‐Carpintero, Rocio, Checketts, Daniel, Sahebkar, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314914/
https://www.ncbi.nlm.nih.gov/pubmed/35175622
http://dx.doi.org/10.1111/epi.17199
_version_ 1784754433263927296
author Wu, Joyce Y.
Cock, Hannah R.
Devinsky, Orrin
Joshi, Charuta
Miller, Ian
Roberts, Colin M.
Sanchez‐Carpintero, Rocio
Checketts, Daniel
Sahebkar, Farhad
author_facet Wu, Joyce Y.
Cock, Hannah R.
Devinsky, Orrin
Joshi, Charuta
Miller, Ian
Roberts, Colin M.
Sanchez‐Carpintero, Rocio
Checketts, Daniel
Sahebkar, Farhad
author_sort Wu, Joyce Y.
collection PubMed
description OBJECTIVE: To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo‐controlled, phase 3 trial in patients with drug‐resistant epilepsy associated with tuberous sclerosis complex (TSC). METHODS: Patients received plant‐derived pharmaceutical formulation of highly purified CBD (Epidiolex; 100 mg/ml oral solution) at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or placebo for 16 weeks (4‐week titration, 12‐week maintenance). Treatment started at 5 mg/kg/day for all groups and reached 25 mg/kg/day on Day 9 and 50 mg/kg/day on Day 29. Percentage change from baseline in TSC‐associated seizure (countable focal or generalized) count was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated. RESULTS: Of 224 patients, 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo. Median (range) age was 11.3 (1.1–56.8) years. Patients had discontinued a median (range) of 4 (0–15) antiseizure medications and were currently taking 3 (0–5). Difference in seizure reduction between CBD and placebo emerged on Day 6 (titrated dose, 15 mg/kg/day) and became nominally significant (p < .049) by Day 10. Separation between placebo and CBD in ≥50% responder rate also emerged by Day 10. Onset of AEs occurred during the first 2 weeks of the titration period in 61% of patients (CBD25, 61%; CBD50, 67%; placebo, 54%). In patients with an AE, resolution occurred within 4 weeks of onset in 42% of placebo and 27% of CBD patients and by end of trial in 78% of placebo and 51% of CBD patients. SIGNIFICANCE: Onset of treatment effect occurred within 6–10 days. AEs lasted longer for CBD than placebo, but the most common (diarrhea, decreased appetite, and somnolence) resolved during the 16‐week trial in most patients.
format Online
Article
Text
id pubmed-9314914
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93149142022-07-30 Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6 Wu, Joyce Y. Cock, Hannah R. Devinsky, Orrin Joshi, Charuta Miller, Ian Roberts, Colin M. Sanchez‐Carpintero, Rocio Checketts, Daniel Sahebkar, Farhad Epilepsia Research Article OBJECTIVE: To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo‐controlled, phase 3 trial in patients with drug‐resistant epilepsy associated with tuberous sclerosis complex (TSC). METHODS: Patients received plant‐derived pharmaceutical formulation of highly purified CBD (Epidiolex; 100 mg/ml oral solution) at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or placebo for 16 weeks (4‐week titration, 12‐week maintenance). Treatment started at 5 mg/kg/day for all groups and reached 25 mg/kg/day on Day 9 and 50 mg/kg/day on Day 29. Percentage change from baseline in TSC‐associated seizure (countable focal or generalized) count was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated. RESULTS: Of 224 patients, 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo. Median (range) age was 11.3 (1.1–56.8) years. Patients had discontinued a median (range) of 4 (0–15) antiseizure medications and were currently taking 3 (0–5). Difference in seizure reduction between CBD and placebo emerged on Day 6 (titrated dose, 15 mg/kg/day) and became nominally significant (p < .049) by Day 10. Separation between placebo and CBD in ≥50% responder rate also emerged by Day 10. Onset of AEs occurred during the first 2 weeks of the titration period in 61% of patients (CBD25, 61%; CBD50, 67%; placebo, 54%). In patients with an AE, resolution occurred within 4 weeks of onset in 42% of placebo and 27% of CBD patients and by end of trial in 78% of placebo and 51% of CBD patients. SIGNIFICANCE: Onset of treatment effect occurred within 6–10 days. AEs lasted longer for CBD than placebo, but the most common (diarrhea, decreased appetite, and somnolence) resolved during the 16‐week trial in most patients. John Wiley and Sons Inc. 2022-03-04 2022-05 /pmc/articles/PMC9314914/ /pubmed/35175622 http://dx.doi.org/10.1111/epi.17199 Text en © 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Article
Wu, Joyce Y.
Cock, Hannah R.
Devinsky, Orrin
Joshi, Charuta
Miller, Ian
Roberts, Colin M.
Sanchez‐Carpintero, Rocio
Checketts, Daniel
Sahebkar, Farhad
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
title Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
title_full Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
title_fullStr Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
title_full_unstemmed Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
title_short Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
title_sort time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: post hoc analysis of randomized controlled phase 3 trial gwpcare6
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314914/
https://www.ncbi.nlm.nih.gov/pubmed/35175622
http://dx.doi.org/10.1111/epi.17199
work_keys_str_mv AT wujoycey timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6
AT cockhannahr timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6
AT devinskyorrin timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6
AT joshicharuta timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6
AT millerian timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6
AT robertscolinm timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6
AT sanchezcarpinterorocio timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6
AT checkettsdaniel timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6
AT sahebkarfarhad timetoonsetofcannabidioltreatmenteffectandresolutionofadverseeventsintuberoussclerosiscomplexposthocanalysisofrandomizedcontrolledphase3trialgwpcare6